Navigation Links
Anti-Clotting Drug May Cause Severe Bleeding With No Benefit
Date:7/25/2011

By Steven Reinberg
HealthDay Reporter

SUNDAY, July 24 (HealthDay News) -- For patients suffering chest pain, adding a new anti-clotting drug, Eliquis, to dual antiplatelet therapy may result in severe bleeding without reducing the risk of heart attack and stroke, a new study finds.

A trial evaluating the combination treatment was halted early when the risk of severe bleeding among those taking Eliquis (apixaban) became apparent.

"It is very clear there is an increased risk of bleeding, and in most patients it doesn't appear there is a lot of benefit to outweigh the risk of bleeding," said researcher Dr. John H. Alexander, co-director of cardiovascular research at the Duke Clinical Research Institute of Duke University Medical Center in Durham, N.C.

"We know high-risk patients with acute coronary syndromes continue to have events, and we know antiplatelet therapy is effective," said Alexander. The researchers expected to see some increase in bleeding when they added Eliquis to other anti-clotting therapy, but the bleeding was significant and "there was nothing to offset that increase in bleeding, so we stopped the trial," he said.

The conclusion: "Combination treatment with an anticoagulant and dual antiplatelet therapy should be avoided unless there is a clear indication for both, as in some patients with atrial fibrillation," Alexander said.

The report was published online July 24 in the New England Journal of Medicine to coincide with presentation of the study results at the International Society on Thrombosis and Haemostasis Congress, July 23-28 in Kyoto, Japan.

For the study, researchers randomly assigned 7,392 patients who were receiving standard antiplatelet therapy with two drugs to an additional 5 milligrams of Eliquis or a dummy pill twice daily. The study was double-blind, meaning that neither the patients nor the researchers knew who was taking Eliquis or a dummy pill.

Eliquis is a so-called Xa inhibitor, which is a class of anticoagulants that work by blocking factor X, a protein involved in blood clotting.

Over an average follow-up of eight months, 7.5 percent of the patients receiving Eliquis had a heart attack, suffered a stroke, or died, as did 7.9 percent of the patients receiving placebo, the researchers found.

In addition, 1.3 percent of those taking Eliquis had major bleeding, compared with 0.5 percent of those receiving the placebo, they noted.

Moreover, more patients taking Eliquis had bleeding into the brain and died from uncontrollable bleeding than patients receiving placebo, Alexander said.

Would a lower dose of Eliquis work? Alexander is skeptical. While it could reduce the risk of bleeding, he said he doubts more heart attacks, strokes or deaths would be prevented.

The trial was funded by Pfizer/Bristol-Myers Squibb, the makers of Eliquis.

Commenting on the study, Dr. Gregg C. Fonarow, a professor of cardiology at the University of California, Los Angeles, said that "each year more than 1.4 million men and women are admitted to hospitals in the United States with acute coronary syndromes."

Despite conventional therapy, patients with acute coronary syndromes remain at risk for recurrent cardiovascular events, Fonarow said.

A number of medications that prevent blood clots (known as antithrombotic drugs) "are being evaluated in patients with acute coronary syndromes to determine if they can further reduce cardiovascular event risk without substantially increasing the bleeding risk when added to conventional therapies," he said.

Apixaban and two other drugs, rivaroxaban (Xarelto) and dabigatran (Pradaxa), have been shown to provide significant benefit in reducing stroke and clots in patients with atrial fibrillation, where the benefit outweighs the bleeding risk, Fonarow said.

"However, this new study suggests that the use of apixaban, at least at the dose studied, should be avoided in patients with recent acute coronary syndromes being treated with dual antiplatelet therapy," he said.

More information

For more information on heart disease, visit the U.S. Centers for Disease Control and Prevention.

SOURCES: John H. Alexander, M.D., co-director, Cardiovascular Research, Duke Clinical Research Institute, Duke University Medical Center, Durham, N.C.; Gregg C. Fonarow, M.D., professor, cardiology, University of California, Los Angeles; July 24, 2011, New England Journal of Medicine, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Tests to Measure Safety of Anti-Clotting Drugs of Limited Value
2. Extended use of anti-clotting drug helps some bedridden patients
3. New Anti-Clotting Drug May Work Better After Hip Replacement
4. Anti-clotting agent does not improve outcomes of patients with severe pneumonia
5. Obstructive Sleep Apnea in Kids May Have Genetic Cause
6. UCLA study reveals how genes interact with their environment to cause disease
7. Virus Unlikely to Cause Chronic Fatigue Syndrome
8. RSA Innovator NetClarity Solves Networking Problems Caused by HP and Cisco Divorce
9. Popular nanoparticle causes toxicity in fish, study shows
10. Genetic cause discovered for rare bleeding disorder
11. Contact Dermatitis Can Be Irritating, Especially When the Cause is a Mystery
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Anti-Clotting Drug May Cause Severe Bleeding  With No Benefit
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... Las Vegas, Nevada (PRWEB) , ... June 24, ... ... their Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and ... The Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... America . ... ... ... ...
(Date:6/23/2016)... 2016  Experian Health, the healthcare industry ... patient payment and care experience, today announced ... and services that will enhance the breadth ... These award-winning solutions will enable healthcare professionals ... in an ever-changing environment and redefine front-office ...
Breaking Medicine Technology: